TP53 and ovarian carcinoma: Olaparib inhibits SLC7A11 expression by upregulating p53 in ovarian cancer cells, and then affects glutathione synthesis, resulting in the accumulation of lipid peroxidation and ferroptosis (Hong et al., 2021).